The response rate in our study is identical to the ORR of 22% (2/9 patients) in a phase II study of 12 patients with advanced melanoma who received TIL-ACT with a low-dose IL-2 regimen (125 000 IU/kg over 12 days).14 This evidence concerns the gene IL2 and melanoma.